Heidarian examined the dose‐dependent effects of carvacrol in human prostate cancer cell lines, which significantly reduced IL‐6 gene expression as compared to the control group in which IL‐6 protein reduced 41.5% and 52.7% at 360 and 420 μM. This evidence concerns the gene IL6 and prostate carcinoma.